#1 Clinical Trials Search in Europe

L-SERINE

L-Serine, a naturally occurring amino acid found in foods like soy products, seaweeds, sweet potatoes, eggs, and meat, is currently being investigated as a potential treatment for several neurological disorders. Clinical trials are examining its efficacy in conditions including Amyotrophic Lateral Sclerosis (ALS), Hereditary Sensory Neuropathy Type 1 (HSN1), and early Alzheimer’s Disease. These studies aim to determine if L-Serine can slow disease progression, improve neurological function, or reduce neurotoxic compounds that may contribute to these conditions. The research is particularly promising as L-Serine is generally recognized as safe by the FDA and is already widely available as a dietary supplement.

Table of Contents

What is L-Serine?

L-Serine is a naturally occurring amino acid found in the human body and in many foods. It is considered a non-essential amino acid because the body can produce some L-serine on its own, particularly through astrocytes (supporting cells) in the brain[1]. Despite being classified as “non-essential,” L-serine plays crucial roles in many bodily functions and has emerged as a potential therapeutic agent for several neurological conditions.

L-Serine is involved in important processes in the body, including:

  • The biosynthesis (production) of purines and pyrimidines, which are building blocks of DNA and RNA
  • The production of other amino acids
  • The formation of phospholipids needed for cell membranes
  • Serving as sites for phosphorylation (a process that regulates protein function) within proteins[1]

The U.S. Food and Drug Administration (FDA) considers L-serine “Generally Recognized as Safe” (GRAS) and has approved it as a normal food additive. It is widely available as a dietary supplement[1].

How L-Serine Works in the Body

To understand how L-serine works therapeutically, it’s helpful to look at the specific conditions being studied. For example, in Hereditary Sensory Neuropathy Type 1 (HSN1), a genetic mutation causes an enzyme called serine palmitoyltransferase (SPT) to function abnormally. Instead of using L-serine as its preferred substrate, the mutated enzyme begins using other amino acids like alanine and glycine, which leads to the production of toxic compounds called deoxysphingoid bases (DSBs)[2].

These toxic compounds can damage nerves, causing symptoms of the disease. Supplementing with L-serine is thought to work by providing a higher concentration of the enzyme’s preferred substrate, effectively “outcompeting” the other amino acids and reducing the production of the toxic compounds[2].

In the case of Amyotrophic Lateral Sclerosis (ALS), the mechanism appears to be related to a neurotoxin called β-methylamino-L-alanine (BMAA). Research suggests that BMAA can be misincorporated into proteins in place of L-serine, leading to protein misfolding, aggregation, and eventually cell death. High doses of L-serine may help prevent this misincorporation by competing with BMAA[3].

Medical Conditions Treated with L-Serine

Based on clinical trials, L-serine is being investigated as a potential treatment for several neurological conditions:

1. Amyotrophic Lateral Sclerosis (ALS)

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. L-serine has been studied in ALS patients to assess its safety, tolerability, and potential efficacy[4][3]. The hypothesis is that L-serine may help prevent the misincorporation of the neurotoxin BMAA into proteins, which could slow disease progression.

2. Hereditary Sensory Neuropathy Type 1 (HSN1)

HSN1 is a rare genetic disorder characterized by progressive loss of sensation, particularly in the feet and legs, often leading to injuries, ulcers, and even amputations. It’s caused by mutations in genes (SPTLC1 or SPTLC2) that affect the enzyme serine palmitoyltransferase[2][5]. L-serine supplementation aims to reduce the production of toxic deoxysphingolipids that damage nerves.

3. Early-Stage Alzheimer’s Disease

L-serine has also been investigated for its potential benefits in early-stage Alzheimer’s disease, a progressive disorder that causes brain cells to degenerate and die, leading to memory loss and cognitive decline. The exact mechanism for how L-serine might help in Alzheimer’s is still being researched[1].

Dosage Information

The dosages of L-serine used in clinical trials vary depending on the condition being treated:

  • For ALS: Doses ranging from 0.5 grams twice daily up to 15 grams twice daily have been studied[3][4].
  • For HSN1: A dose of 400 mg/kg/day (divided into three daily doses) has been used. For an average adult weighing 75 kg, this would be approximately 30 grams per day[2][5].
  • For Early Alzheimer’s Disease: A dose of 15 grams twice daily (30 grams total per day) has been studied[1].

It’s important to note that these are doses used in controlled clinical trials. Patients should never self-administer L-serine at these levels without medical supervision, as individual needs may vary and safety monitoring is essential.

How L-Serine is Administered

In clinical trials, L-serine has been administered in various forms:

  • As a powder that can be dissolved in water and taken orally[5]
  • In gummy form, with each gummy containing 1 gram of L-serine[1]

Some trials have used a gradual dose increase (ramp-up) approach to help patients adjust to the medication and assess tolerability. For example, in the Alzheimer’s disease trial, patients started with a lower dose that was gradually increased over a 4-week period[1].

Side Effects and Tolerability

L-serine appears to be generally well-tolerated at the doses studied in clinical trials. However, some side effects have been reported:

  • Gastrointestinal (GI) symptoms have been the most commonly reported side effects[4]
  • In the ALS studies, tolerability was assessed based on participant self-reported GI symptoms[4]

Studies have monitored various safety parameters, including:

  • Complete blood count
  • Liver function tests
  • Basic metabolic panel measurements[1]

Given that L-serine is an amino acid that affects the balance of other amino acids in the body, some trials have specifically monitored amino acid balances in blood samples to ensure safety[1].

Clinical Evidence and Ongoing Research

L-serine is still considered an experimental treatment for the conditions mentioned. Clinical trials have been designed to assess various aspects:

For ALS:

  • Phase IIa studies have evaluated tolerability and preliminary efficacy[4]
  • The ALS Functional Rating Scale-Revised (ALSFRS-R) has been used to measure disease progression. This scale assesses patients’ capabilities in 12 functional activities, with scores ranging from 0 (no function) to 48 (normal function)[4]
  • Forced Vital Capacity (FVC), a measure of lung function, has also been used to assess disease progression[4]

For HSN1:

  • Randomized, double-blind, placebo-controlled studies have measured the effect of L-serine on disease progression[2][5]
  • The Charcot Marie Tooth Neuropathy Score (CMTNS) has been used to assess disease severity[2]
  • Intraepidermal nerve fiber density (IENFD) from skin biopsies has been measured to assess the effect on nerve fibers[2]
  • Levels of toxic deoxysphingolipids in blood have been monitored to confirm the biological effect of L-serine[2]
  • Some studies are using MRI to track changes in muscle fat fraction as a measure of disease progression[5]

For Alzheimer’s Disease:

  • Phase IIa studies have used the Montreal Cognitive Assessment (MoCA) to evaluate cognitive function. This assessment evaluates eight domains of cognitive functions, with scores ranging from 0 to 30 (higher scores indicate better function)[1]
  • Blood biomarkers related to cognitive status have also been monitored[1]

Dietary Sources of L-Serine

L-serine is naturally present in many foods. Good dietary sources include:

  • Soy products
  • Some edible seaweeds
  • Sweet potatoes
  • Eggs
  • Meat[1][1]

However, the amounts of L-serine obtained from diet alone are much lower than the therapeutic doses being studied in clinical trials. For treatment purposes, pharmaceutical-grade L-serine supplements would be required under medical supervision.

Condition Study Design Dosage Primary Outcomes Key Findings/Status
Amyotrophic Lateral Sclerosis (ALS) Phase IIa trial to assess tolerability and efficacy 15 grams twice daily for 6 months Dose tolerability based on subject reporting, ALS Functional Rating Scale-Revised (ALSFRS-R), Forced Vital Capacity (FVC) The studies are evaluating if L-Serine can slow disease progression in ALS patients, potentially by preventing neurotoxin (BMAA) incorporation into proteins
Hereditary Sensory Neuropathy Type 1 (HSN1) Randomized, double-blind, placebo-controlled crossover study 400mg/kg/day for 1-2 years Charcot Marie Tooth Neuropathy Score, Intraepidermal Nerve Fiber Density, MRI Muscle Fat Fraction L-Serine may compete with and prevent the accumulation of neurotoxic deoxysphingolipids that occur due to genetic mutations in the SPT enzyme
Early Alzheimer’s Disease Phase IIa, randomized, double-blind, placebo-controlled trial 15 grams twice daily (via gummies) for 9 months Montreal Cognitive Assessment score changes, plasma biomarker levels Investigating if L-Serine supplementation can affect cognitive function in early Alzheimer’s disease patients

FAQ

  • What is L-Serine and why is it being studied in neurological disorders? L-Serine is a naturally occurring dietary amino acid found in foods like soy products, seaweeds, sweet potatoes, eggs, and meat. It's being studied in neurological disorders because research suggests it may help prevent the formation of certain neurotoxic compounds. In conditions like Hereditary Sensory Neuropathy Type 1 (HSN1), mutations cause the production of harmful deoxysphingolipids instead of normal sphingolipids. L-Serine supplementation may help correct this biochemical imbalance. In ALS, it may have neuroprotective effects, while in Alzheimer's Disease, it might help with cognitive function.
  • What doses of L-Serine are being tested in clinical trials? The clinical trials are testing various doses of L-Serine. In ALS studies, doses up to 15 grams twice daily (30 grams total per day) are being evaluated. For Hereditary Sensory Neuropathy Type 1, trials are using weight-based dosing of 400mg/kg/day. In the Alzheimer's Disease trial, patients received L-Serine through gummies, with a target dose of 15 grams twice daily (30 grams total). Some trials include a dose ramp-up period to assess tolerability before reaching the full therapeutic dose.
  • How is L-Serine administered in these clinical trials? In these clinical trials, L-Serine is typically administered orally. The methods vary by study, including powder form dissolved in water, or as gummies containing 1g of L-Serine each. For example, in the Alzheimer's Disease trial, patients took 15 gummies (each containing 1g of L-Serine) twice daily. The dosing schedule is usually divided throughout the day, such as twice daily dosing, to improve tolerability. The treatment duration in these trials ranges from 6 months to 2 years, depending on the specific study protocol.
  • What outcomes are researchers measuring in L-Serine clinical trials? Researchers are measuring various outcomes depending on the disease being studied. For ALS, they're assessing functional ability using the ALS Functional Rating Scale-Revised (ALSFRS-R) and pulmonary function tests like Forced Vital Capacity (FVC). In HSN1 trials, they're measuring nerve fiber density in skin biopsies, the Charcot Marie Tooth Neuropathy Score, and muscle fat fraction on MRI. For Alzheimer's Disease, cognitive function is being evaluated using the Montreal Cognitive Assessment. Many studies also measure biomarkers in blood samples, such as deoxysphingolipid levels or neurofilament light chain, to understand the biological effects of L-Serine treatment.
  • Is L-Serine considered safe for human consumption? L-Serine is considered generally recognized as safe (GRAS) by the FDA and has been approved as a normal food additive. It is already widely sold as a dietary supplement. The clinical trials are designed to further evaluate the safety and tolerability of L-Serine at therapeutic doses. In the early studies, researchers are carefully monitoring for any adverse events, with special attention to gastrointestinal symptoms which might occur at higher doses. Safety monitoring in these trials includes blood tests for complete blood counts, liver function, and basic metabolic panels to ensure there are no concerning changes during treatment.

Ongoing Clinical Trials on L-SERINE

  • Study on the Impact of Acetylcysteine and Drug Combination on Kidney Function in Living Donor Kidney Transplant Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • L-Serine: A naturally occurring amino acid found in foods like soy products, seaweed, sweet potatoes, eggs, and meat. It plays important roles in the body including protein synthesis and is being studied as a potential treatment for several neurological disorders.
  • Amyotrophic Lateral Sclerosis (ALS): A progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. It is also known as Lou Gehrig's disease.
  • Hereditary Sensory Neuropathy Type 1 (HSN1): A rare inherited disorder characterized by progressive loss of sensation, particularly in the feet and legs, often leading to ulcers and infections. It's caused by mutations in genes like SPTLC1 and SPTLC2.
  • Deoxysphingolipids (DSBs): Abnormal lipid compounds that can accumulate in HSN1 patients due to genetic mutations. These compounds are thought to be neurotoxic (harmful to nerve cells).
  • β-methylamino-L-alanine (BMAA): A non-protein amino acid that some research suggests may be linked to neurodegenerative diseases like ALS. L-serine supplementation might prevent BMAA from being incorrectly incorporated into proteins.
  • Serine Palmitoyltransferase (SPT): An enzyme that normally uses L-serine to produce sphingolipids. Mutations in genes encoding this enzyme (SPTLC1 and SPTLC2) can cause HSN1 by altering the enzyme's preferred substrate.
  • ALS Functional Rating Scale-Revised (ALSFRS-R): A 48-point scale used to measure the functional status of ALS patients. It assesses 12 different functional activities, with higher scores indicating better function.
  • Forced Vital Capacity (FVC): A pulmonary function test that measures the amount of air a person can exhale after taking a deep breath. In ALS patients, this measurement helps track respiratory muscle strength.
  • Intraepidermal Nerve Fiber Density (IENFD): A measurement of small nerve fibers in the skin obtained through skin biopsy. Decreased density indicates nerve damage and is used to monitor peripheral neuropathies.
  • Montreal Cognitive Assessment (MoCA): A screening tool used to assess cognitive impairment. It evaluates different cognitive domains including memory, attention, and language, with scores ranging from 0 to 30 (higher is better).
  • Charcot Marie Tooth Neuropathy Score (CMTNS): A clinical assessment scale used to measure disease severity in peripheral neuropathies, including HSN1. It evaluates sensory symptoms, motor symptoms, and nerve conduction tests.
  • Neurofilament Light Chain: A protein released when nerve cells are damaged. Blood levels can be measured as a biomarker of neurodegeneration in conditions like ALS and HSN1.
  • Placebo-Controlled Trial: A study design where some participants receive the treatment being tested (L-serine) while others receive an inactive substance (placebo). This helps determine if observed effects are due to the treatment itself.
  • Muscle Fat Fraction: A measurement obtained through MRI that quantifies the amount of fat within muscles. Increased fat fraction indicates muscle degeneration in conditions like HSN1.
  • Double-Blind Study: A research design where neither the participants nor the researchers know who is receiving the actual treatment versus placebo until after the study is completed, reducing potential bias.

References

  1. https://clinicaltrials.gov/study/NCT03062449
  2. https://clinicaltrials.gov/study/NCT01733407
  3. https://clinicaltrials.gov/study/NCT01835782
  4. https://clinicaltrials.gov/study/NCT03580616
  5. https://clinicaltrials.gov/study/NCT06113055